NO20100656L - Modifiserte chimaere polypeptider med forbedrede farmakokinetiske egenskaper - Google Patents
Modifiserte chimaere polypeptider med forbedrede farmakokinetiske egenskaperInfo
- Publication number
- NO20100656L NO20100656L NO20100656A NO20100656A NO20100656L NO 20100656 L NO20100656 L NO 20100656L NO 20100656 A NO20100656 A NO 20100656A NO 20100656 A NO20100656 A NO 20100656A NO 20100656 L NO20100656 L NO 20100656L
- Authority
- NO
- Norway
- Prior art keywords
- vegf
- pharmacokinetic properties
- chimeric polypeptides
- improved pharmacokinetic
- modified chimeric
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
Abstract
Det er beskrevet anvendelse av et fusjonspolypeptid som er i stand til å binde vaskulær endotelial vekstfaktor (VEGF) for fremstilling av et medikament til behandling av en øyesykdom eller artritt, hvor fusjonspolypeptidet består i hovedsak av et immunoglobulinliknende (Ig) domene 2 av en første VEGF-reseptor og Ig-domene 3 av en andre VEGF-reseptor samt en multimeriserende komponent. Særskilte sykdommer som kan behandles med de aktuelle medikamenter er diabetisk retinopati eller reumatoid artritt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13813399P | 1999-06-08 | 1999-06-08 | |
PCT/US2000/014142 WO2000075319A1 (en) | 1999-06-08 | 2000-05-23 | Modified chimeric polypeptides with improved pharmacokinetic properties |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20100656L true NO20100656L (no) | 2002-02-08 |
NO332559B1 NO332559B1 (no) | 2012-10-29 |
Family
ID=22480568
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20016036A NO330775B1 (no) | 1999-06-08 | 2001-12-10 | Isolert nukleinsyremolekyl som koder for vaskulaer endotelial vekstfaktor med immunoglobulin-domener, fusjonspolypeptid kodet av dette, fremgangsmate for fremstilling derav samt anvendelse derav |
NO20100656A NO332559B1 (no) | 1999-06-08 | 2010-05-06 | Anvendelse av fusjonspolypeptid for fremstilling av medikamenter til behandling av oyesykdommer |
NO2013010C NO2013010I1 (no) | 1999-06-08 | 2013-05-15 | Aflibercept |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20016036A NO330775B1 (no) | 1999-06-08 | 2001-12-10 | Isolert nukleinsyremolekyl som koder for vaskulaer endotelial vekstfaktor med immunoglobulin-domener, fusjonspolypeptid kodet av dette, fremgangsmate for fremstilling derav samt anvendelse derav |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2013010C NO2013010I1 (no) | 1999-06-08 | 2013-05-15 | Aflibercept |
Country Status (33)
Country | Link |
---|---|
EP (2) | EP1544299B1 (no) |
JP (2) | JP4723140B2 (no) |
KR (1) | KR100659477B1 (no) |
CN (3) | CN103349781B (no) |
AT (2) | ATE417928T1 (no) |
AU (2) | AU779303B2 (no) |
BE (1) | BE2013C029I2 (no) |
BR (2) | BR0011407A (no) |
CA (1) | CA2376379C (no) |
CY (2) | CY1108883T1 (no) |
CZ (2) | CZ303656B6 (no) |
DE (2) | DE60019415T2 (no) |
DK (2) | DK1544299T3 (no) |
ES (2) | ES2237429T3 (no) |
FR (1) | FR13C0028I2 (no) |
HK (3) | HK1043388A1 (no) |
HR (1) | HRP20010908B1 (no) |
HU (3) | HU230159B1 (no) |
IL (3) | IL146890A0 (no) |
LT (1) | LTC1183353I2 (no) |
LU (1) | LU92195I2 (no) |
ME (2) | ME00024B (no) |
MX (1) | MXPA01012630A (no) |
NO (3) | NO330775B1 (no) |
NZ (1) | NZ515913A (no) |
PL (1) | PL208247B1 (no) |
PT (2) | PT1183353E (no) |
RS (1) | RS50073B (no) |
RU (1) | RU2265661C2 (no) |
SK (1) | SK287332B6 (no) |
UA (1) | UA74146C2 (no) |
WO (1) | WO2000075319A1 (no) |
ZA (1) | ZA200110068B (no) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710174B2 (en) | 2001-09-13 | 2004-03-23 | Isis Pharmaceuticals, Inc. | Antisense inhibition of vascular endothelial growth factor receptor-1 expression |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのF1t4(VEGFR−3)および抗腫瘍療法 |
US6734017B2 (en) | 2001-09-28 | 2004-05-11 | Isis Pharmaceuticals, Inc. | Antisense modulation of vascular endothelial growth factor receptor-2 expression |
DE60336341D1 (de) | 2002-05-04 | 2011-04-21 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur förderung des neuronalen wachstums |
ES2278333T3 (es) * | 2003-03-28 | 2007-08-01 | Regeneron Pharmaceuticals, Inc. | Antagonistas de vegf para el tratamiento de la diabetes. |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
MX351062B (es) * | 2003-05-16 | 2017-09-29 | Acorda Therapeutics Inc | Proteinas de fusion para el tratamiento del snc. |
ES2887949T3 (es) | 2003-05-16 | 2021-12-29 | Acorda Therapeutics Inc | Mutantes degradantes de proteoglicanos para el tratamiento del SNC |
WO2004106378A2 (en) * | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using vegf antagonists |
US7186699B2 (en) | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
US7399612B2 (en) | 2003-06-30 | 2008-07-15 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
WO2005016369A1 (en) * | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
CA2566731C (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
PL1767546T3 (pl) * | 2004-06-08 | 2012-07-31 | Chengdu Kanghong Biotechnologies Co Ltd | Hamujące angiogenezę białka chimeryczne i ich zastosowanie |
MXPA06014421A (es) | 2004-06-10 | 2007-05-04 | Regeneron Pharma | Uso de inhibidores de vegf para el tratamiento de cancer humano. |
US20050281822A1 (en) * | 2004-06-18 | 2005-12-22 | Cedarbaum Jesse M | Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion |
JP4807802B2 (ja) * | 2004-07-30 | 2011-11-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Vegf媒介性活性をブロックすることによるi型糖尿病を処置する方法 |
WO2006031689A2 (en) | 2004-09-13 | 2006-03-23 | Genzyme Corporation | Multimeric constructs |
FR2878749B1 (fr) * | 2004-12-03 | 2007-12-21 | Aventis Pharma Sa | Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives |
WO2006088650A2 (en) * | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
ZA200708845B (en) | 2005-03-25 | 2010-07-28 | Regeneron Pharma | Vegf antogonist formulations |
CA2623635C (en) | 2005-09-26 | 2013-04-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
CA2630839C (en) † | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
FR2895258B1 (fr) | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
JP5216002B2 (ja) | 2006-06-16 | 2013-06-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 硝子体内投与に適したvegfアンタゴニスト製剤 |
BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
US7722864B2 (en) | 2006-10-10 | 2010-05-25 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
FR2918279B1 (fr) * | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
CN101575379B (zh) * | 2008-05-09 | 2012-05-30 | 上海抗体药物国家工程研究中心有限公司 | 可溶性vegfr双功能融合受体、其制备方法及用途 |
RU2550258C2 (ru) | 2008-11-03 | 2015-05-10 | Молекьюлар Партнерс Аг | Связывающие белки, ингибирующие взаимодействия vegf-a рецептора |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
ES2895226T3 (es) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensivos |
AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
HUE035554T2 (en) | 2010-08-06 | 2018-05-02 | Genzyme Corp | VEGF antagonist compositions and their uses |
EP2662385A4 (en) * | 2011-01-07 | 2015-11-11 | Chugai Pharmaceutical Co Ltd | METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES |
SG10201802789VA (en) | 2011-01-13 | 2018-05-30 | Regeneron Pharma | Use of a vegf antagonist to treat angiogenic eye disorders |
JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
CN104159926B (zh) | 2011-12-01 | 2019-02-01 | 圆祥生命科技有限公司 | 补体和vegf途径的蛋白质抑制剂及其使用方法 |
CN103304668B (zh) * | 2012-03-12 | 2015-10-28 | 江苏健德生物药业有限公司 | Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用 |
PT2846836T (pt) | 2012-05-07 | 2019-10-29 | Allergan Inc | Método de tratamento de dmi em doentes refratários à terapia anti-vegf |
WO2014006113A1 (en) | 2012-07-03 | 2014-01-09 | Sanofi | Method of treating cancer by effective amounts of aflibercept |
TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以dll4拮抗劑治療卵巢癌之方法 |
EP3693381A1 (en) | 2013-02-18 | 2020-08-12 | Vegenics Pty Limited | Ligand binding molecules and uses thereof |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CN104193828B (zh) * | 2013-09-12 | 2017-04-05 | 北京韩美药品有限公司 | 同时阻断her2和vegfr信号通路的重组融合蛋白 |
WO2015069668A1 (en) | 2013-11-05 | 2015-05-14 | Allergan, Inc. | Method of treating conditions of the eye with an anti-vegf darpin |
WO2015173260A1 (en) | 2014-05-12 | 2015-11-19 | Formycon Ag | Pre-filled plastic syringe containing a vegf antagonist |
ES2732925T3 (es) | 2014-07-18 | 2019-11-26 | Sanofi Sa | Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer |
JP2016036322A (ja) * | 2014-08-11 | 2016-03-22 | 日本化薬株式会社 | 血管新生因子と結合するキメラタンパク質 |
CN112826934A (zh) | 2014-12-11 | 2021-05-25 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
GB201503453D0 (en) | 2015-03-01 | 2015-04-15 | Jain Arjun | Endothelin-1"sponge" |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
WO2017046140A1 (en) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
KR101936049B1 (ko) * | 2015-10-15 | 2019-01-08 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 생산방법 |
WO2017065559A1 (ko) | 2015-10-15 | 2017-04-20 | (주)알테오젠 | Igg fc 도메인을 가지는 융합 단백질의 생산방법 |
CN108883057A (zh) | 2015-11-18 | 2018-11-23 | Sio2医药产品公司 | 用于眼科配制品的药物包装 |
RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
MX2018006171A (es) | 2015-11-18 | 2018-12-19 | Formycon Ag | Jeringa de plastico precargada que contiene un antagonista de vegf. |
CA3005391A1 (en) * | 2015-11-19 | 2017-05-26 | Zhuhai Tairuishang Biopharm Ltd. | Methods and compositions for binding vegf |
FI3384049T3 (fi) | 2015-12-03 | 2023-09-25 | Regeneron Pharma | Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä |
CA3011638C (en) | 2016-01-26 | 2023-01-10 | Formycon Ag | Liquid formulation of a vegf antagonist |
EP3527225A4 (en) | 2016-10-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENT |
US11135266B2 (en) | 2016-11-21 | 2021-10-05 | Just-Evotec Biologics, Inc. | Aflibercept formulations and uses thereof |
EP3630043A1 (en) | 2017-05-24 | 2020-04-08 | Formycon AG | Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist |
WO2018215580A1 (en) | 2017-05-24 | 2018-11-29 | Formycon Ag | Method for sterilizing prefilled plastic syringes containing a vegf antagonist |
CA3063995A1 (en) | 2017-05-24 | 2018-11-29 | Sio2 Medical Products, Inc. | Sterilizable pharmaceutical package for ophthalmic formulations |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
CN111344410B (zh) | 2017-08-17 | 2023-09-15 | 济世易为生物有限公司 | 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法 |
EP3713591A1 (en) | 2017-11-20 | 2020-09-30 | Just-Evotec Biologics, Inc. | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
AU2018372235B9 (en) * | 2017-11-27 | 2022-03-10 | 4D Molecular Therapeutics Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
LT3716992T (lt) | 2017-11-30 | 2022-09-12 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto panaudojimas akių angiogeninių sutrikimų gydymui |
BR112020011072A2 (pt) | 2017-12-13 | 2020-11-17 | Regeneron Pharmaceuticals, Inc. | dispositivos e sistemas para gerenciamento de suporte de leito de coluna cromatográfica e métodos relacionados |
CA3089481A1 (en) * | 2018-01-26 | 2019-08-01 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN111378044B (zh) | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
EP3969564A1 (en) | 2019-05-16 | 2022-03-23 | Formycon AG | Method for reducing methionine oxidation in recombinant proteins |
JP2022546082A (ja) | 2019-09-03 | 2022-11-02 | アムジエン・インコーポレーテツド | 薬物送達のための注入デバイス及び注入デバイスのためのパッケージ |
CA3150482A1 (en) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
AU2020393842A1 (en) | 2019-11-25 | 2022-06-16 | The Regents Of The University Of California | Long-acting VEGF inhibitors for intraocular neovascularization |
BR112021025438A2 (pt) | 2019-12-06 | 2022-06-21 | Regeneron Pharma | Composições de proteínas anti-vegf e métodos para produzir as mesmas |
CA3163876A1 (en) | 2019-12-06 | 2021-06-10 | Regeneron Pharmaceuticals, Inc. | Vegf mini-traps and methods of use thereof |
MX2022010177A (es) | 2020-02-24 | 2022-09-12 | Amgen Inc | Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos. |
EP4145456A1 (en) | 2021-09-06 | 2023-03-08 | Bayer AG | Prediction of a change related to a macular fluid |
WO2024029876A1 (ko) * | 2022-08-02 | 2024-02-08 | 주식회사 파노로스바이오사이언스 | 변형된 융합 단백질 및 이의 용도 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
-
2000
- 2000-05-23 EP EP05001328A patent/EP1544299B1/en not_active Expired - Lifetime
- 2000-05-23 DE DE60019415T patent/DE60019415T2/de not_active Expired - Lifetime
- 2000-05-23 PL PL352246A patent/PL208247B1/pl active Protection Beyond IP Right Term
- 2000-05-23 CA CA002376379A patent/CA2376379C/en not_active Expired - Lifetime
- 2000-05-23 PT PT00932721T patent/PT1183353E/pt unknown
- 2000-05-23 AT AT05001328T patent/ATE417928T1/de active
- 2000-05-23 NZ NZ515913A patent/NZ515913A/xx not_active IP Right Cessation
- 2000-05-23 AU AU50404/00A patent/AU779303B2/en active Active
- 2000-05-23 RU RU2002100071/13A patent/RU2265661C2/ru active Protection Beyond IP Right Term
- 2000-05-23 KR KR1020017015839A patent/KR100659477B1/ko active Protection Beyond IP Right Term
- 2000-05-23 CZ CZ20100386A patent/CZ303656B6/cs not_active IP Right Cessation
- 2000-05-23 ME MEP-2008-32A patent/ME00024B/me unknown
- 2000-05-23 PT PT05001328T patent/PT1544299E/pt unknown
- 2000-05-23 CZ CZ20014387A patent/CZ302689B6/cs unknown
- 2000-05-23 ME MEP-32/08A patent/MEP3208A/xx unknown
- 2000-05-23 DE DE60041159T patent/DE60041159D1/de not_active Expired - Lifetime
- 2000-05-23 AT AT00932721T patent/ATE293164T1/de active
- 2000-05-23 DK DK05001328T patent/DK1544299T3/da active
- 2000-05-23 EP EP00932721A patent/EP1183353B1/en not_active Expired - Lifetime
- 2000-05-23 HU HU1300086A patent/HU230159B1/hu unknown
- 2000-05-23 ES ES00932721T patent/ES2237429T3/es not_active Expired - Lifetime
- 2000-05-23 HU HU0201515A patent/HU229156B1/hu active Protection Beyond IP Right Term
- 2000-05-23 SK SK1752-2001A patent/SK287332B6/sk not_active IP Right Cessation
- 2000-05-23 JP JP2001502582A patent/JP4723140B2/ja not_active Expired - Lifetime
- 2000-05-23 BR BR0011407-3A patent/BR0011407A/pt not_active IP Right Cessation
- 2000-05-23 MX MXPA01012630A patent/MXPA01012630A/es active IP Right Grant
- 2000-05-23 RS YUP-869/01A patent/RS50073B/sr unknown
- 2000-05-23 CN CN201310118971.1A patent/CN103349781B/zh not_active Expired - Lifetime
- 2000-05-23 UA UA2001128378A patent/UA74146C2/uk unknown
- 2000-05-23 BR BRPI0011407A patent/BRPI0011407B8/pt unknown
- 2000-05-23 CN CNB008115443A patent/CN100523187C/zh not_active Expired - Lifetime
- 2000-05-23 IL IL14689000A patent/IL146890A0/xx unknown
- 2000-05-23 WO PCT/US2000/014142 patent/WO2000075319A1/en active Application Filing
- 2000-05-23 ES ES05001328T patent/ES2319305T3/es not_active Expired - Lifetime
- 2000-05-23 DK DK00932721T patent/DK1183353T3/da active
- 2000-05-23 CN CN2008101093559A patent/CN101433715B/zh not_active Expired - Lifetime
-
2001
- 2001-12-03 IL IL146890A patent/IL146890A/en active Protection Beyond IP Right Term
- 2001-12-06 ZA ZA200110068A patent/ZA200110068B/xx unknown
- 2001-12-07 HR HR20010908A patent/HRP20010908B1/xx not_active IP Right Cessation
- 2001-12-10 NO NO20016036A patent/NO330775B1/no active Protection Beyond IP Right Term
-
2002
- 2002-07-04 HK HK02105009A patent/HK1043388A1/xx not_active IP Right Cessation
-
2005
- 2005-03-31 AU AU2005201365A patent/AU2005201365B2/en not_active Expired
-
2008
- 2008-03-17 IL IL190234A patent/IL190234A0/en not_active IP Right Cessation
-
2009
- 2009-03-16 CY CY20091100288T patent/CY1108883T1/el unknown
- 2009-11-05 HK HK09110323.8A patent/HK1132653A1/xx unknown
-
2010
- 2010-05-06 NO NO20100656A patent/NO332559B1/no not_active IP Right Cessation
- 2010-10-06 JP JP2010226970A patent/JP5273746B2/ja not_active Expired - Lifetime
-
2013
- 2013-05-13 CY CY2013019C patent/CY2013019I2/el unknown
- 2013-05-13 BE BE2013C029C patent/BE2013C029I2/fr unknown
- 2013-05-14 LU LU92195C patent/LU92195I2/fr unknown
- 2013-05-14 FR FR13C0028C patent/FR13C0028I2/fr active Active
- 2013-05-14 LT LTPA2013009C patent/LTC1183353I2/lt unknown
- 2013-05-15 NO NO2013010C patent/NO2013010I1/no unknown
- 2013-09-17 HU HUS1300052C patent/HUS1300052I1/hu unknown
- 2013-11-26 HK HK13113191.5A patent/HK1185798A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20100656L (no) | Modifiserte chimaere polypeptider med forbedrede farmakokinetiske egenskaper | |
Esposito et al. | The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor | |
Lock et al. | Two elements target SIV Nef to the AP‐2 clathrin adaptor complex, but only one is required for the induction of CD4 endocytosis | |
WO1997000319A3 (en) | Chimeric leptin fused to immunoglobulin domain and use | |
WO2007112675A8 (fr) | Protéine de fusion du récepteur du vegf et son utilisation | |
UA105625C2 (uk) | Пастка vegf і її терапевтичне застосування | |
Kao et al. | A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response | |
DK203489A (da) | Anti-t-celle receptor determinanter til diagnosticering og behandling af autoimmune sygdomme | |
DE69821132D1 (de) | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes | |
ATE169675T1 (de) | Modifizierter menschlicher tumornekrosisfaktor- alpha-rezeptor | |
EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
DE60040293D1 (de) | Verwendung von nikotin in der angiogenese und der vaskulogenese | |
DK0686161T3 (da) | Alfa-underenhed af humane beta2-integriner | |
DE69733179D1 (de) | Modifizierte chimäre superantigene und deren verwendung | |
ATE342358T1 (de) | Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen | |
DE68918867D1 (de) | Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen. | |
EP1378245A3 (en) | Transferrin binding proteins from neisseria gonorrhoeae and neisseria meningitidis. Their use in a vaccine | |
NO952336L (no) | Insulin analoger | |
Bussolino et al. | Dynamic modules and heterogeneity of function: a lesson from tyrosine kinase receptors in endothelial cells | |
Schwarz et al. | The ether-a-go-go-related gene K+ current: functions of a strange inward rectifier | |
DE69631624D1 (de) | Antikörper gegen menschliches restrictin | |
FR2688504B1 (fr) | Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique. | |
Chen et al. | Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity | |
Liu et al. | Effect of atropine on denervated rabbit ear blood vessels | |
SETTON | Ph. D. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |